Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Moderna reported a quarterly loss of $2.50 per share, which was better than the Zacks Consensus Estimate of a loss of$ 2.69, and a significant decline from earnings of $0.55 per share a year ago, indicating a 7.06% earnings surprise [1] - The company generated revenues of$ 966 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.04%, but down from $2.81 billion in the same quarter last year [2] - Moderna has consistently exceeded consensus EPS estimates over the last four quarters, with a notable surprise of 101.59% in the previous quarter [2][1] Financial Performance - The stock has underperformed, losing approximately 23.2% since the beginning of the year, while the S&P 500 has gained 4% [3] - The current consensus EPS estimate for the upcoming quarter is -$ 2.85, with expected revenues of $234.83 million, and for the current fiscal year, the estimate is -$ 8.72 on $2.3 billion in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Moderna's stock may be influenced by the overall industry outlook, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]